LILRB1
Leukocyte immunoglobulin-like receptor subfamily B member 1 precursor (LIR-1) (Leukocyte immunoglobulin-like receptor 1) (CD85 antigen-like family member J) (Immunoglobulin-like transcript 2) (ILT-2) (Monocyte/macrophage immunoglobulin-like receptor 7) (MIR-7) (CD85j antigen) [ILT2] [LIR1] [MIR7]
Publications[править]
NK cell receptors (NKR) are expressed in subsets of NK and CD8 T cells, lymphocytes involved in multiple sclerosis (MS) pathogenesis. Clinical implications of NKR expression in MS are unknown. Here, we show that the proportions of CD8 T cells displaying LILRB1, an inhibitory NKR expressed at late stages of T cell differentiation, were directly related with age and MS duration, and inversely with the immunomodulatory therapy-dependent increase of CD56(bright) NK cells. Similar associations were found for KIR and CD56 CD8 T cells, whereas no age-related NKR distribution was perceived in controls. Moreover, active MS had lower LILRB1 NK cells, and IFN-β-treated patients exhibited a phenotypic profile related to shorter disease evolution. Progressive accumulation of terminally differentiated T lymphocytes and experienced NK cells in MS, presumably stimulated in response to a persistent challenge and modulated by IFN-β therapy, may support the analysis of NKR distribution as new biomarkers.
MeSH Terms
- Adult
- Aging
- Antibodies
- Antigens, CD
- Biomarkers
- CD56 Antigen
- CD8-Positive T-Lymphocytes
- Cell Count
- Cytomegalovirus Infections
- Female
- Humans
- Interferon-beta
- Killer Cells, Natural
- Leukocyte Immunoglobulin-like Receptor B1
- Leukocytes, Mononuclear
- Lymphocytes
- Male
- Middle Aged
- Multiple Sclerosis
- Multiple Sclerosis, Chronic Progressive
- Multiple Sclerosis, Relapsing-Remitting
- NK Cell Lectin-Like Receptor Subfamily C
- Receptors, Immunologic
- Receptors, KIR
- Receptors, Natural Killer Cell
- Recurrence
- Time Factors